56705-86-3 Usage
Uses
Used in Pharmaceutical Industry:
4-(3-METHOXYPHENOXY)ANILINE is used as a pharmaceutical intermediate for the synthesis of various organic compounds and drug candidates. Its unique chemical structure allows it to be a versatile building block in the development of new medications.
Used in Chemical Synthesis:
4-(3-METHOXYPHENOXY)ANILINE is used as a key component in the synthesis of various organic compounds, contributing to the creation of a wide range of chemical products.
Used in Dyes and Pigments Production:
4-(3-METHOXYPHENOXY)ANILINE is used as a raw material in the production of dyes and pigments, providing color and stability to various products in the textile, paint, and printing industries.
Check Digit Verification of cas no
The CAS Registry Mumber 56705-86-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,6,7,0 and 5 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 56705-86:
(7*5)+(6*6)+(5*7)+(4*0)+(3*5)+(2*8)+(1*6)=143
143 % 10 = 3
So 56705-86-3 is a valid CAS Registry Number.
InChI:InChI=1/C13H13NO2/c1-15-12-3-2-4-13(9-12)16-11-7-5-10(14)6-8-11/h2-9H,14H2,1H3
56705-86-3Relevant academic research and scientific papers
HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY
-
Paragraph 0135; 0143; 0144, (2020/06/19)
The present invention provides a novel heterocyclic compound represented by Formula [I] and a salt thereof: wherein the symbols are as defined in the specification, which is useful for treating, preventing and/or diagnosing seizure and the like in disease involving epileptic seizure or convulsive seizure (including multiple drug resistant seizure, refractory seizure, acute symptomatic seizure, febrile seizure and status epilepticus), as well as a medical use therefor.
4-Substituted anilides as selective melatonin MT2 receptor agonists
Epperson, James R.,Deskus, Jeffrey A.,Gentile, Anthony J.,Iben, Lawrence G.,Ryan, Elaine,Sarbin, Nathan S.
, p. 1023 - 1026 (2007/10/03)
A series of 4-substituted anilides with human melatonergic affinity is reported. Butyramides 26, 39, 42, 52, 57, and 58 all demonstrated subnanomolar MT2 binding affinity and MT2 selectivity of at least 70-fold over the MT1 receptor. Compound 26 demonstrated full agonism at the MT2 receptor.
